Venom Immunotherapy in Patients with Clonal Mast Cell Disorders: Efficacy, Safety, and Practical Considerations

Journal of Allergy and Clinical Immunology: In Practice

Volumn 1, Issue 5, 2013, Pages 474-478

  Bonadonna, Patrizia ^a   Gonzalez de Olano, David ^b   Zanotti, Roberta ^a   Riccio, Annamaria ^c   De Ferrari, Laura ^c   Lombardo, Carla ^a   Rogkakou, Anthi ^c   Escribano, Luis ^d   Alvarez Twose, Ivan ^d   Matito, Almudena ^d   Vega, Arantza ^e   Passalacqua, Giovanni ^c  

^a UNIVERSITY OF VERONA   (Italy)

^b HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^c UNIVERSITY OF GENOA   (Italy)

^d HOSPITAL VIRGEN DE LA SALUD   (Spain)

^e HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

Author keywords

Efficacy; Hymenoptera allergy; Safety; Systemic mastocytosis; Venom immunotherapy

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; INSECT VENOM; TRYPTASE; ARTHROPOD VENOM;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INSECT ALLERGY; ITALY; MAJOR CLINICAL STUDY; MALE; MASTOCYTOSIS; OBSERVATIONAL STUDY; PRESCRIPTION; PRICK TEST; PROSPECTIVE STUDY; RADIOALLERGOSORBENT TEST; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPAIN; TREATMENT OUTCOME; ANIMAL; CLINICAL TRIAL; DESENSITIZATION; HYMENOPTERA; HYPERSENSITIVITY; IMMUNOLOGY; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ARTHROPOD VENOMS; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; HYMENOPTERA; HYPERSENSITIVITY; MALE; MASTOCYTOSIS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84883376532     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2013.06.014     Document Type: Article

References (33)

1. Valent P., Akin C., Escribano L., Fodinger M., Hartman K., Brockow K., et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007, 37:435-453.
2. Castells M., Austen K.F. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol 2002, 127:147-152.
3. Alvarez-Twose I., Gonzalez-de-Olano D., Sanchez-Munoz Ll Clinical, biological and molecular characteristics of systemic mast cell disorders presenting with severe mediator-related symptoms. JAllergy Clin Immunol 2010, 125:1269-1278.
4. Akin C., Valent P., Metcalfe D.D. Mast cell activation syndrome: proposed diagnostic criteria. JAllergy Clin Immunol 2010, 126:1099-1104.
5. Valent P., Akin C., Arock M., Brockow K., Butterfield J.H., Carter M.C., et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012, 157:215-225.
6. Valent P., Horny H.P., Escribano L., Longley B.J., Li C.Y., Schwartz L.B., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001, 25:603-625.
7. Ludolph-Hauser D., Rueff F., Fries C., Schopf P., Przybilla B. Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reaction to Hymenoptera sting. Lancet 2001, 357:361-362.
8. Biedermann T., Rueff F., Sander C.A., Przybilla B. Mastocytosis associated with severe wasp sting anaphylaxis detected by elevated serum mast cell tryptase levels. Br J Dermatol 1999, 141:1110-1112.
9. Bonadonna P., Zanotti R., Pagani M., Caruso B., Perbellini O., Colarossi S., et al. How much specific is the association between Hymenoptera venom allergy and mastocytosis?. Allergy 2009, 64:1379-1382.
10. Oude Elberink J.N., de Monchy J., Kors J.V., Doormaal J.J., Dubois A.E. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. JAllergy Clin Immunol 1997, 99:153-154.
11. Dubois A.E. Mastocytosis and Hymenoptera allergy. Curr Opin Allergy Clin Immunol 2004, 4:291-295.
12. Fricker M., Helbling A., Schwartz L., Müller U. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. JAllergy Clin Immunol 1997, 100:11-15.
13. Bonadonna P., Zanotti R., Caruso B., Castellani L., Perbellini O., Colarossi S., et al. Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy. JAllergy Clin Immunol 2008, 121:256-257.
14. Gonzalez-de-Olano D., Alvarez-Twose I., Esteban-López M.I., Sánchez-Muñoz L., de Durana M.D., Vega A., et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. JAllergy Clin Immunol 2008, 121:519-526.
15. Bilò B.M., Rueff F., Mosbech H., Bonifazi F., Oude-Elberink J.N.G. the EAACI Interest Group on Insect Venom Hypersensitivity. Diagnosis of Hymenoptera venom allergy. Allergy 2005, 60:1339-1349.
16. Bonifazi F., Jutel M., Biló B.M., Birnbaum J., Muller U. EAACI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005, 60:1459-1470.
17. Bonadonna P., Perbellini O., Passalacqua G., Caruso B., Colarossi S., Zanotti P., et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. JAllergy Clin Immunol 2009, 123:680-686.
18. Sanchez-Munoz L., Teodosio C., Morgado J.M., Escribano L. Immunophenotypic characterization of bone marrow mast cells in mastocytosis and other mast cell disorders. Methods Cell Biol 2011, 103:333-359.
19. Escribano L., Orfao A., Diaz-Agustin B. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998, 91:2731-2736.
20. Akin C. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. JMol Diagn 2006, 8:412-419.
21. Sotlar K., Escribano L., Landt O., Möhrle S., Herrero S., Torrelo A., et al. One-step detection of c-kit point mutations using PNA-mediated PCR-clamping and hybridization probes. Am J Pathol 2003, 162:737-746.
22. Muller R.U. Insect sting allergy: clinical picture, diagnosis and treatment. Gustav Fischer Ed 1990, 3:33.
23. Golden D.B.K., Valentine M.D., Kagey-Sobotka A., Lichtenstein L.M. Regimens of Hymenoptera venom immunotherapy. Ann Intern Med 1980, 92:620-624.
24. Severino M., Bonadonna P., Passalacqua G. Large local reactions from stinging insects: from epidemiology to management. Curr Opin Allergy Clin Immunol 2009, 9:334-337.
25. Zanotti R., Bonadonna P., Bonifacio M., Caruso B., Colato C., De Matteis G., et al. La mastocitosi sistemica: un approccio multidiscliplinare. Biochim Clin 2012, 36:158-170.
26. Niedoszykto M., DeMonchy J., vanDoormal J.J., Jassem E., Oude Elberink J.N.G. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009, 64:1237-1245.
27. Bonadonna P., Zanotti R., Melioli G., Antonini F., Romano I., Lenzi G., et al. The role of basophil activation test in special populations with mastocytosis and reactions to hymenoptera sting. Allergy 2012, 67:962-965.
28. Bonadonna P., Zanotti R., Müller U. Mastocytosis and insect venom allergy. Curr Opin Allergy Clin Immunol 2010, 10:347-353.
29. González-de-Olano D., Alvarez-Twose I., Vega A., Orfao A., Escribano L. Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis. Immunotherapy 2011, 3:637-651.
30. Incorvaia C., Frati F., Dell'Albani I., Robino A., Cattaneo E., Mauro M., et al. Safety of hymenoptera venom immunotherapy: a systematic review. Expert Opin Pharmacother 2011, 12:2527-2532.
31. Ruëff F., Chatelain R., Przybilla B. Management of occupational Hymenoptera allergy. Curr Opin Allergy Clin Immunol 2011, 11:69-74.
32. Alvarez-Twose I., Bonadonna P., Matito A., Zanotti R., González-de-Olano D., Sánchez-Muñoz L., et al. Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis. JAllergy Clin Immunol 2013, 131:614-615.
33. Simioni L., Vianello A., Bonadonna P., Marcer G., Severino M., Pagani M., et al. Efficacy of venom immunotherapy given every 3 or 4 months: a prospective comparison with the conventional regimen. Ann Allergy Asthma Immunol 2013, 110:51-54.